You are here: Industry Insights > NASH

News List

Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at AASLD event expresspharma
November 04, 2020
Zydus announced that a Late-Breaker Oral Presentation and two Poster Presentations on Saroglitazar Mg has been accepted for presentation at The Liver Meeting 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) ...
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH prnewswire
October 21, 2020
Akero Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to efruxifermin (EFX), an investigational FGF21 analog for the treatment of NASH.
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist prnasia
October 16, 2020
Gannex Pharma Co. announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic steatohepatitis (NASH) indication.
Gannex receives US IND Approval for NASH drug candidate, an FXR agonist expresspharma
October 14, 2020
In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis.
Owlstone Medical’s breath biopsy test improves detection of liver disease pharmatimes
September 27, 2020
Cambridge-based Owlstone Medical has announced new results from a study of its breath-based diagnostic test for liver disease, including Nonalcoholic Fatty Liver Disease (NAFLD) and associated Nonalcoholic steatohepatitis (NASH).
Intercept to Cut 25% of Workforce after NASH Treatment Rejection from FDA americanpharmaceuticalreview
September 07, 2020
Intercept Pharmaceuticals plans to lay off 25% of its workforce, approximately 170 jobs, after its nonalcoholic steatohepatitis (NASH) treatment application for obeticholic acid (OCA) was rejected by the U.S. Food and Drug Administration (FDA).
Takeda signs deal with UK biotech Engitix pharmatimes
August 26, 2020
Takeda has signed a licensing agreement with UK biotech Engitix to develop new therapies for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).
Metacrine Announces MET409 Receives FDA Fast Track Designation for NASH Treatment americanpharmaceuticalreview
August 26, 2020
Metacrine announced the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Merck licences NASH drug efinopegdutide from Hanmi pharmaceutical-technology
August 05, 2020
Merck (MSD) has signed an exclusive licensing agreement with Hanmi Pharmaceutical to develop, manufacture and commercialise efinopegdutide (formerly HM12525A) to treat nonalcoholic steatohepatitis (NASH).
End of the line for Genfit's experimental NASH drug pharmatimes
July 23, 2020
Genfit has announced the termination of a late-stage trial testing elafibranor for treatment of nonalcoholic steatohepatitis (NASH) with fibrosis.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page